COVID-19 Virus Infection Clinical Trial
Official title:
Pilot Phase II Randomized, Placebo-Controlled Clinical Trial for the Prevention and Progression of SARS-CoV-2 Infection of Subjects and Patients Using a Supplement Treatment With Carnipure Tartrate ( LCLT)
The purpose of the study is to assess safety and efficacy of Carnipure tartrate (L-Carnitine and L-tartaric acid - LCLT) supplementation for SARS-Cov-2 infection
After being informed about the study and potential risks, all patients given written informed consent will be divided em two cohorts according to inclusion criteria.One group with patients with diagnosed mild SARS-Cov-2 infection and another with healthy contacts of patients with diagnosed mild SARS-Cov-2. Both groups will be randomized to receive either LCLT supplementation or placebo during 21 days. After this period primary endpoints of efficacy will be assessed. Clinical follow up evaluations will be monitored (Cohort 1 and 2), and chest tomography will be monitored in cohort 2 as well. Subjects will be followed for safety through 8 weeks (cohort 1) and 6 weeks (cohort 2) after being included into the study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04560881 -
Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)
|
Phase 3 | |
Terminated |
NCT04449380 -
Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT05208983 -
SafeTy and Efficacy of Preventative CoVID Vaccines
|
||
Completed |
NCT05364268 -
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
|
||
Completed |
NCT05268679 -
Covid-19 Vaccine Response in Heart Transplant Recipients
|
||
Terminated |
NCT04847583 -
A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients
|
Phase 2 | |
Terminated |
NCT04778059 -
Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
|
Phase 2 | |
Terminated |
NCT04786808 -
Risk Factors for COVID-19 Mortality
|
||
Completed |
NCT05514691 -
Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC
|
N/A | |
Withdrawn |
NCT05085574 -
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
|
Phase 2 | |
Completed |
NCT05489367 -
Does COVÄ°D-19 m-RNA Vaccine Affect Fertility and Over Reserve ?
|
||
Withdrawn |
NCT05133635 -
High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19
|
Phase 4 | |
Active, not recruiting |
NCT05077332 -
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
|
Phase 2 | |
Terminated |
NCT05077969 -
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)
|
Phase 2 | |
Completed |
NCT05371561 -
Effect of PPE on Children's Fear in Dental Office
|
N/A |